

30<sup>th</sup> July 2024

## **A MOMENTOUS MILESTONE FOR THE CF COMMUNITY**

Following yesterday's announcement, we extend our deepest gratitude to all who made this significant milestone possible. From this Thursday 1st August, Trikafta will be available on the Pharmaceutical Benefits Scheme (PBS) for children aged 2+ with at least one F508del mutation. This expansion is a monumental step forward for our youngest CF warriors and their families.

We would like to extend a special thanks to:

- Health Minister Mark Butler: Your leadership and commitment have been pivotal in making this possible.
- Vertex Pharmaceuticals: For your dedication to developing and providing access to life-changing treatments.
- Our Dedicated Federation Members: Your tireless advocacy and support have driven this success.
- Our CF Community Members: Your voices, stories, and persistence have been instrumental in this journey.
- Everyone Involved: Your collective efforts have led to this incredible achievement.

We've heard numerous stories from those in older age groups who describe Trikafta as 'life-changing', and we are excited about the positive impact this will have on our young CF warriors.

We would also like to share a heartfelt thanks:

- Heath, Ashley, and Lucas: Thank you for sharing your story at yesterday's event and illustrating the profound impact this will have on your lives.
- Professor Claire Wainwright: For sharing your expertise in paediatric respiratory health, providing invaluable insights into the significance of this advancement.

Thank you to everyone who attended the announcement on such short notice. We eagerly look forward to hearing how this new access to Trikafta benefits you and your loved ones.

However, we recognize there is still much to be done to ensure all individuals living with CF have access to the necessary treatments and therapies without experiencing additional financial burdens.

Together, we will continue to advocate for and support our CF community, striving for a future where everyone living with cystic fibrosis has affordable access to the treatments and therapies they need.

*“Jo Armstrong who leads the CF community, the cystic fibrosis community, through the terrific organisation, Cystic Fibrosis Australia, that is just such a compelling, powerful advocacy group, harnessing the ambitions of all of these families and the many, many others beyond Canberra to get the sorts of life changing treatments that we’re able to announce today.” - Minister Mark Butler*

We are deeply thankful for Minister Butler's commendation of Cystic Fibrosis Australia's advocacy efforts. You can read the full announcement transcript [HERE](#).

Warm Regards,

Jo Armstrong  
CEO  
Cystic Fibrosis Australia